Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Total Current Liabilities (2016 - 2025)

Dare Bioscience (DARE) has disclosed Total Current Liabilities for 11 consecutive years, with $21.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities rose 61.27% year-over-year to $21.2 million, compared with a TTM value of $21.2 million through Sep 2025, up 61.27%, and an annual FY2024 reading of $21.6 million, up 5.53% over the prior year.
  • Total Current Liabilities was $21.2 million for Q3 2025 at Dare Bioscience, up from $19.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $31.6 million in Q4 2022 and bottomed at $6.0 million in Q2 2021.
  • Average Total Current Liabilities over 5 years is $18.7 million, with a median of $19.2 million recorded in 2025.
  • The sharpest move saw Total Current Liabilities skyrocketed 175.39% in 2022, then plummeted 50.06% in 2024.
  • Year by year, Total Current Liabilities stood at $16.1 million in 2021, then skyrocketed by 97.0% to $31.6 million in 2022, then tumbled by 35.24% to $20.5 million in 2023, then rose by 5.53% to $21.6 million in 2024, then dropped by 1.84% to $21.2 million in 2025.
  • Business Quant data shows Total Current Liabilities for DARE at $21.2 million in Q3 2025, $19.2 million in Q2 2025, and $21.2 million in Q1 2025.